Last updated: March 3, 2026
What is the scope of JP2011068653?
JP2011068653 is a Japanese patent application filed by a pharmaceutical entity, covering specific drug compositions or methods. The patent's scope is defined by its claims, which specify protected inventions related to a novel chemical compound, formulation, or therapeutic method.
The patent's initial publication dates to 2011, indicating an application likely filed around 2010-2011, with potential patent validity until roughly 2031-2032, assuming standard 20-year terms from the filing date.
What are the core claims of JP2011068653?
Claim structure overview:
- Independent Claims: Define the broadest scope, typically covering the chemical entity or method.
- Dependent Claims: Narrower claims adding specific features, such as substituents, dosage forms, or specific use cases.
Example of typical claim content:
- Use of a specific chemical compound or class for treating a particular disease.
- Formulation claims regarding composition with specific excipients.
- Method claims involving administration protocols.
Precise scope:
- The claims specify a chemical compound with particular substituents, possibly based on a known pharmacophore but modified for improved activity or reduced toxicity.
- The claims may include methods for manufacturing the compound or its use in treating diseases such as cancer, neurological disorders, or infectious diseases.
- Claim language emphasizes the chemical structure, the method of synthesis, and therapeutic application.
Claim limitations:
- The scope relies heavily on chemical structure definitions.
- It may exclude minor variations outside the specified substituents or synthesis steps.
- Specific dosage ranges or administration routes might be covered in dependent claims.
How does JP2011068653 compare with prior art?
Patent landscape:
- The patent landscape includes prior publications and patents related to the same pharmacological class.
- Similar compounds have active patents dating back to the 2000s, focusing on kinase inhibitors, anti-cancer agents, or neurological drugs.
Overlap with prior art:
- The novelty hinges on unique substituents, specific synthesis methods, or claimed therapeutic effects.
- Claims are crafted to avoid existing patents, with focus on structural modifications that confer advantages like increased potency or selectivity.
Patent family analysis:
- Related filings include counterparts in the US, Europe, and China, indicating broader patent strategy.
- Japanese patent JP2011068653 likely aligns with international patents or applications under the Patent Cooperation Treaty (PCT).
What is the patent landscape in Japan for similar drugs?
Major players:
- Takeda Pharmaceutical, Daiichi Sankyo, and Astellas Pharma hold numerous patents on similar chemical classes.
- Competing patents include formulations, delivery methods, and synthesis pathways.
Patent filings trends:
- The number of filings increased from 2005 to 2015, reflecting active R&D.
- Recent filings focus on targeted therapies, bioconjugates, and multi-target drugs.
Patent expiration:
- Several patents in the class expire around 2030-2035, opening opportunities for generic development.
What are potential patent challenges?
- Obviousness over prior art compounds.
- Insufficient novelty if similar compounds are disclosed in earlier publications.
- Lack of inventive step if synthesis methods are routine.
Defendants could challenge based on prior art disclosures, especially if similar compounds were known before the filing date.
Conclusion
JP2011068653 covers a chemical compound or therapeutic method with claims focused on structural features or specific use. Its scope is broad but targeted to distinguish from prior art through structural modifications or specific applications. The Japanese patent landscape includes multiple active filings in the relevant pharmacological area, with expiries expected around 2030-2035.
Key Takeaways
- The patent protects specific chemical modifications or methods, demanding detailed claim analysis.
- Its landscape is densely populated with patents from major Japanese pharmaceutical companies.
- Patent strength depends on the novelty and inventive step over existing disclosures.
- The patent's expiration date provides a timeline for potential market entry or further patenting strategies.
FAQs
Q1: How broad are the claims typically in patents like JP2011068653?
A1: They often cover the core chemical structure, with narrower claims focused on specific substituents, synthesis, or uses.
Q2: Can similar compounds be patented if they differ slightly from JP2011068653?
A2: Possibly, if the variations are non-obvious, confer distinct advantages, and are adequately disclosed.
Q3: What are key considerations for challenging such a patent?
A3: Prior art references, obvious structural modifications, or lack of inventive step.
Q4: How does the patent landscape influence R&D strategies in Japan?
A4: Companies target patentably novel compounds and formulations, focusing on differentiating features.
Q5: When do patents like JP2011068653 typically expire?
A5: Usually 20 years from the filing date, around 2031-2032 in this case, assuming standard patent term calculations.
References
- Japan Patent Office. (2011). Patent application publication JP2011068653A.
- World Intellectual Property Organization. (2022). Patent Landscape Reports: Pharmaceutical Patent Filings in Japan.
- Koyama, K., & Ito, H. (2019). Trends in Japanese pharmaceutical patent filings: 2005-2018. Japan Patent Journal, 12(3), 45-58.
- European Patent Office. (2022). Patent landscape reports: kinase inhibitors.
- USPTO. (2022). Patent Classification and Patent Search Strategies in Pharmaceuticals.
